Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK.

AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614.

PMID:
28832410
2.

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N.

BMC Infect Dis. 2017 Aug 9;17(1):551. doi: 10.1186/s12879-017-2626-z. Review.

3.

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Clemmons DR, Miller S, Mamputu JC.

PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017.

4.

Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.

Erlandson KM, Fiorillo SP, Cardoso SW, Riviere C, Sanchez J, Hakim J, Kumarasamy N, Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT.

AIDS Res Hum Retroviruses. 2017 Sep;33(9):929-934. doi: 10.1089/AID.2016.0327. Epub 2017 May 16.

PMID:
28403619
5.

Biochemical Manifestation of HIV Lipodystrophy Syndrome.

Ihenetu K, Mason D.

Int J MCH AIDS. 2012;1(1):92-101. Review.

6.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.

7.

Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.

Stanley TL, Grinspoon SK.

Growth Horm IGF Res. 2015 Apr;25(2):59-65. doi: 10.1016/j.ghir.2014.12.005. Epub 2014 Dec 20. Review.

8.

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.

JAMA. 2014 Jul 23-30;312(4):380-9. doi: 10.1001/jama.2014.8334.

9.

Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.

Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ, Andersen O, Imami N.

Clin Exp Immunol. 2013 Sep;173(3):444-53. doi: 10.1111/cei.12141.

10.

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

Glesby MJ, Albu J, Chiu YL, Ham K, Engelson E, He Q, Muthukrishnan V, Ginsberg HN, Donovan D, Ernst J, Lesser M, Kotler DP.

PLoS One. 2013 Apr 12;8(4):e61160. doi: 10.1371/journal.pone.0061160. Print 2013.

11.

Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.

Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS.

Endocr Rev. 2013 Jun;34(3):377-412. doi: 10.1210/er.2012-1053. Epub 2013 Mar 8. Review.

12.

Leptin revisited: its mechanism of action and potential for treating diabetes.

Coppari R, Bjørbæk C.

Nat Rev Drug Discov. 2012 Sep;11(9):692-708. doi: 10.1038/nrd3757. Review.

13.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.

14.

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

Bedimo R.

HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10.

15.

Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.

Fitch K, Grinspoon S.

Am J Clin Nutr. 2011 Dec;94(6):1721S-1728S. doi: 10.3945/ajcn.111.012120. Epub 2011 Nov 16. Review.

16.

Management of the metabolic effects of HIV and HIV drugs.

Brown TT, Glesby MJ.

Nat Rev Endocrinol. 2011 Sep 20;8(1):11-21. doi: 10.1038/nrendo.2011.151. Review.

Supplemental Content

Support Center